Capricor Therapeutics
CAPR
Market cap $349M

7.64 USD

-3.76

32.98%

At close Jul 11, 4:00 PM EDT

After hours

7.57

-0.07

0.92%

1 day

-32.98%

5 days

-22.83%

1 month

-41.86%

3 months

-17.76%

6 months

-39.94%

Year to date

-48.93%

1 year

66.45%

5 years

87.25%

10 years

-84.72%

About: Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Employees: 160

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 6 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

92% more repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 24

68% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 19

47% more call options, than puts

Call options by funds: $17M | Put options by funds: $11.6M

11% more funds holding

Funds holding: 108 [Q4 2024] → 120 (+12) [Q1 2025]

2.0% more ownership

Funds ownership: 38.11% [Q4 2024] → 40.11% (+2.0%) [Q1 2025]

27% less capital invested

Capital invested by funds: $239M [Q4 2024] → $174M (-$65.2M) [Q1 2025]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]

See Fund Rankings

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$21

175%

upside

Avg. target

$26

242%

upside

High target

$31

306%

upside

6 analyst ratings

6 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Joseph Pantginis	214%upside $24	Buy Maintained	11 Jul 2025
B. Riley Securities Madison El-Saadi	175%upside $21	Buy Initiated	26 Jun 2025
Jones Trading Catherine Novack	280%upside $29	Buy Maintained	25 Jun 2025
Oppenheimer Leland Gershell	188%upside $22	Outperform Maintained	23 Jun 2025
Roth Capital Boobalan Pachaiyappan	306%upside $31	Buy Reiterated	17 Jun 2025

See Analyst Rankings

Financial journalist opinion

Based on 26 articles about CAPR published over the past 30 days

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

OAKLAND, Calif.--(BUSINESS WIRE)---- $CAPR #CAPR--Shares of Capricor Therapeutics, Inc. plunged over 30% in intraday trading on Friday, July 11, 2025, after the U.S. Food and Drug Administration rejected the company's Biologics License Application for its lead cell therapy candidate, Deramiocel, claiming that the application “does not meet the statutory requirement for substantial evidence of effectiveness” and lacks “certain outstanding items.” Gibbs Mura is investigating a potential Capricor Therapeutics, In.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC

ATLANTA, July 11, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) complied with federal securities laws. On July 11, 2025, Capricor announced that it had received a Complete Response Letter (“CRL”) from the FDA regarding its Biologics License Application (“BLA”) for Deramiocel. Following this news, the price of the Company's stock dropped.

INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. (CAPR) Announced by Holzer & Holzer, LLC

Proactive Investors

Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application

Capricor Therapeutics (NASDAQ:CAPR) shares plummeted more than 26% after it reported the US Food and Drug Administration (FDA) has not approved its Biologics License Application for deramiocel, the company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD). In a Complete Response Letter to Capricor, the FDA stated that the application did not meet the statutory requirement for substantial evidence of effectiveness and requested additional clinical data before reconsidering approval.

Capricor Therapeutics shares tumble as FDA rejects Duchenne muscular dystrophy drug application

Investors Business Daily

Capricor Therapeutics Hammered On A Surprise FDA Rejection

Capricor Therapeutics plummeted Friday after the FDA rejected its experimental treatment for cardiomyopathy associated with DMD.

Capricor Therapeutics Hammered On A Surprise FDA Rejection

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Capricor Therapeutics Inc. CAPR stock is trading lower on Friday.

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 300 points on Friday.

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

US FDA declines to approve Capricor's muscle disorder therapy

Capricor Therapeutics said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy for a type of muscle disorder.

US FDA declines to approve Capricor's muscle disorder therapy

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its Biologics License Application (BLA) for Deramiocel, the Company's lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy (DMD).

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR

See News Rankings

Charts implemented using Lightweight Charts™